GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Zhejiang Taimei Medical Technology Co Ltd (HKSE:02576) » Definitions » ROE %

Zhejiang Taimei Medical Technology Co (HKSE:02576) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Zhejiang Taimei Medical Technology Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Zhejiang Taimei Medical Technology Co's annualized net income for the quarter that ended in Dec. 2023 was HK$0.0 Mil. Zhejiang Taimei Medical Technology Co's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was HK$1,266.4 Mil. Therefore, Zhejiang Taimei Medical Technology Co's annualized ROE % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Zhejiang Taimei Medical Technology Co's ROE % or its related term are showing as below:

HKSE:02576' s ROE % Range Over the Past 10 Years
Min: -33.99   Med: -29.95   Max: -19.87
Current: -19.87

During the past 4 years, Zhejiang Taimei Medical Technology Co's highest ROE % was -19.87%. The lowest was -33.99%. And the median was -29.95%.

HKSE:02576's ROE % is ranked worse than
79.33% of 624 companies
in the Healthcare Providers & Services industry
Industry Median: 4.82 vs HKSE:02576: -19.87

Zhejiang Taimei Medical Technology Co ROE % Historical Data

The historical data trend for Zhejiang Taimei Medical Technology Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Taimei Medical Technology Co ROE % Chart

Zhejiang Taimei Medical Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
ROE %
-33.99 -28.90 -29.95 -19.87

Zhejiang Taimei Medical Technology Co Semi-Annual Data
Dec21 Dec22 Dec23 Dec24
ROE % - - - -18.54

Competitive Comparison of Zhejiang Taimei Medical Technology Co's ROE %

For the Health Information Services subindustry, Zhejiang Taimei Medical Technology Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Taimei Medical Technology Co's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Zhejiang Taimei Medical Technology Co's ROE % distribution charts can be found below:

* The bar in red indicates where Zhejiang Taimei Medical Technology Co's ROE % falls into.


;
;

Zhejiang Taimei Medical Technology Co ROE % Calculation

Zhejiang Taimei Medical Technology Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-379.298/( (1462.826+1070.073)/ 2 )
=-379.298/1266.4495
=-29.95 %

Zhejiang Taimei Medical Technology Co's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=0/( (1462.826+1070.073)/ 2 )
=0/1266.4495
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Zhejiang Taimei Medical Technology Co  (HKSE:02576) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=0/1266.4495
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0 / 0)*(0 / 1809.246)*(1809.246 / 1266.4495)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.4286
=ROA %*Equity Multiplier
=N/A %*1.4286
=0.00 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=0/1266.4495
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (0 / 0) * (0 / 0) * (0 / 0) * (0 / 1809.246) * (1809.246 / 1266.4495)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= N/A * N/A * N/A % * 0 * 1.4286
=0.00 %

Note: The net income data used here is one times the annual (Dec. 2023) net income data. The Revenue data used here is one times the annual (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Zhejiang Taimei Medical Technology Co ROE % Related Terms

Thank you for viewing the detailed overview of Zhejiang Taimei Medical Technology Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Taimei Medical Technology Co Business Description

Traded in Other Exchanges
N/A
Address
36 Changsheng South Road, 3rd Floor, Building 9, Smart Industry Innovation Park, Zhejiang, Jiaxing, CHN
Zhejiang Taimei Medical Technology Co Ltd is a digital solution provider focused on the pharmaceutical and medical device industry in China, It designs and delivers industry-specific software and digital services that facilitate the research and development (R&D) as well as the commercialization of pharmaceuticals and medical devices. The software It offers is cloud-based, allowing users to access it from various devices at any time over the internet, without the need for software installation and maintenance on their devices. These cloud-based software covers critical use cases in R&D and commercialization of innovative drugs and medical devices.
Executives
Zuo Lingye 2201 Interest of corporation controlled by you
Shang Hai Jing Wei Gu Quan Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hang Zhou Jing Wei Yuan Chuang Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Jing Wei Chuang Teng Hang Zhou Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Shen Zhen Shi Teng Xun Rui Tou Qi Ye Guan Li You Xian Gong Si
Teng Xun Ke Ji Shen Zhen You Xian Gong Si
Chen Yihai 2202 Interest of your spouse
Shang Hai Chen Xi Chuang Ye Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Shang Hai Yuan Pan Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Xue Qiong 2201 Interest of corporation controlled by you
Ma Huateng
Lin Zhi Teng Xun Tou Zi Guan Li You Xian Gong Si
Shen Zhen Shi Teng Xun Chan Ye Tou Zi Ji Jin You Xian Gong Si
Oriental Power Holdings Limited
Shen Zhen Shi Teng Xun Rui Jian Tou Zi You Xian Gong Si

Zhejiang Taimei Medical Technology Co Headlines

No Headlines